126 related articles for article (PubMed ID: 20229123)
1. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
2. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Wang Y; Wu M; Al-Rousan R; Liu H; Fannin J; Paturi S; Arvapalli RK; Katta A; Kakarla SK; Rice KM; Triest WE; Blough ER
J Pharmacol Exp Ther; 2011 Jan; 336(1):56-63. PubMed ID: 20947636
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
5. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
8. The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.
Banerjee P; Sahoo A; Anand S; Bir A; Chakrabarti S
J Alzheimers Dis; 2016; 49(3):681-93. PubMed ID: 26484920
[TBL] [Abstract][Full Text] [Related]
9. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
[TBL] [Abstract][Full Text] [Related]
10. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
[TBL] [Abstract][Full Text] [Related]
11. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Unal S; Hazirolan T; Eldem G; Gumruk F
Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
[TBL] [Abstract][Full Text] [Related]
12. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
15. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
16. Thalassemia: cardiac iron and chelators.
Gaur A
Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
[No Abstract] [Full Text] [Related]
17. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
Wood JC; Glynos T; Thompson A; Giardina P; Harmatz P; Kang BP; Paley C; Coates TD
Haematologica; 2011 Jul; 96(7):1055-8. PubMed ID: 21393329
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
20. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.
Kamalinia G; Khodagholi F; Atyabi F; Amini M; Shaerzadeh F; Sharifzadeh M; Dinarvand R
Mol Pharm; 2013 Dec; 10(12):4418-31. PubMed ID: 24063264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]